01 · The Goal

Regrow the lung’s air sacs where disease destroys them

The goal is to regrow the alveoli — the tiny air sacs where oxygen enters the blood — that diseases like COPD destroy, so that lost breathing capacity is rebuilt rather than only managed.

02 · Why It Matters

The lungs hold around 300 million alveoli, the delicate air sacs where oxygen crosses into the blood. In COPD and other chronic lung diseases these are destroyed, and breathing capacity is lost — leaving people gasping for air. The lung has real regenerative potential and its own stem cells, but chronic damage overwhelms it. Regrowing alveoli would restore the actual gas-exchange surface — the thing breathing depends on. That is why alveolar regeneration is the flagship of the lungs.

03 · What We’re Trying to Achieve

We are building the capability to reactivate the lung’s own stem cells to regrow alveoli and to rebuild functional gas-exchange tissue — restoring the surface where oxygen enters the body.

04 · How It Works

Reawakening the lung’s own regeneration

Activating lung stem cells Demonstrated in research

The lung carries its own stem cells that can regrow alveoli; researchers are learning to activate them to rebuild air sacs destroyed by disease.

Growing lung tissue Frontier

Lung organoids and bioengineered tissue let scientists grow and study lung in the lab — a path toward replacing destroyed tissue.

Reversing fibrosis Frontier

Unwinding the stiff scarring of pulmonary fibrosis so supple, functional lung can return.

Protecting the gas-exchange surface Clinical

Shielding alveoli from ongoing damage preserves capacity while regeneration advances.

05 · Who’s Building It

Cited as evidence the capability is real — not as partners or endorsers.

Universities & institutes

Academic pulmonary, lung-stem-cell, and lung-bioengineering research centers studying alveolar regeneration and organoids.

Government & programs

National Heart, Lung, and Blood Institute (NHLBI, NIH) · NIH regenerative-medicine programs.

Enabling science base

lung stem-cell biology · alveolar regeneration · lung organoids · anti-fibrotic therapy · airway tissue engineering.

06 · Technologies

The technologies: lung stem-cell activation; lung organoids that model and could supply lung tissue; anti-fibrotic therapies that reverse scarring; and tissue engineering that rebuilds the gas-exchange architecture.

07 · Breakthroughs

Lung stem-cell alveolar regrowth Demonstrated in research

Lung stem cells regrow alveoli in animal and laboratory studies — the basis of regeneration.

Lung organoids Demonstrated

Functional lung organoids grown from stem cells model the tissue and point toward replacement.

Fibrosis reversal Frontier

Therapies to unwind lung scarring are advancing from slowing toward reversing it.

Airway rebuilding Frontier

Regenerating the airway lining and structure is an active research goal.

08 · Remaining Challenges

The honest challenges: the alveolus is architecturally intricate — a regrown air sac must form with its delicate vessel partnership to actually exchange gas. Fibrosis reversal and full tissue regrowth in people are frontier. And the lung’s regeneration must be directed to rebuild functional structure, not disordered tissue. The lung’s natural regeneration is real and being amplified; full alveolar regrowth in disease is frontier, labeled honestly.

09 · Mature Capability

The future, fully built

A person with COPD or lung scarring — short of breath, capacity lost — has their air sacs regrown: the gas-exchange surface rebuilt, scarring reversed, supple breathing restored. Lung tissue becomes something we regrow, not a capacity people slowly lose.

Honest boundary: each item is tagged for where it stands — demonstrated, clinical, or frontier. The science is real, funded, and accelerating. AI supports human clinicians; it never replaces them.
10 · Evidence Vault

The proof, for this capability

Cited as evidence the capability is real, not as partners or endorsers.

Lung stem-cell alveolar regeneration

Lung stem cells regrow alveoli in animal and lab studies. Stage: Demonstrated (research).

Lung organoids

Functional lung organoids grown from stem cells. Stage: Demonstrated.

Fibrosis reversal

Therapies advancing from slowing toward reversing lung scarring. Stage: Frontier.

Honest framing

Real organizations are cited as evidence the capability is real — not as partners or endorsers. Full alveolar regrowth in disease is frontier; we do not claim it is routine.

Help build this future

Every signature grows the movement to make lung regeneration real — and free at the point of need.

Paid for by Michael Floyd for President.

Scroll to Top